Description
A potent and selective CDK inhibitor with IC50 of 0.2uM, 0.65uM, and 0.7uM for CDK5, Cdc2, and CDK2, respectively; weakly inhibits ERK1 and ERK2 (IC50=34uM and 14uM), poorly inhibits CDK4/cyclin D1 and CDK6/cyclin D2 (IC50>100uM); suppresses the proliferation of mammalian cell lines with an average IC50 of 16uM; significantly inhibits growth of The Ewing's sarcoma family of tumors (ESFT) xenografts. Lung Cancer Phase 2 Clinical